YZYali Zhang

Yali Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yali Zhang has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • Na Mi

    Department of Neurology, First Affiliated Hospital of Harbin Medical University, Harbin, China; Department of Neurology, Chifeng Municipal Hospital, Inner Mongolia Autonomous Region, China

    5 shared publications
  • Chao Zhang

    Department of Neurology, Chifeng Municipal Hospital, Inner Mongolia Autonomous Region, China

    4 shared publications
  • Jia Fu

    Chifeng Municipal Hospital Chifeng City Inner Mongolia Autonomous Region China

    4 shared publications
  • Jing Zhao

    Department of Neurology, Chifeng Municipal Hospital, Inner Mongolia Autonomous Region, China

    4 shared publications
  • Lifen Yao

    Department of Neurology, First Affiliated Hospital of Harbin Medical University, Harbin, China

    4 shared publications
  • Lili Ma

    Department of Neurology, Jilin City Hospital of Chemical Industry, Jilin City, China

    2 shared publications

Latest Publications

  • Open Access

    CCNE1 Exerts a Protective Effect on Parkinson's Disease by Regulating Ferroptosis‐Related Proteins

    by Jia Fu, Jing Zhao, Na Mi, Chao Zhang, Yali Zhang, Lifen Yao

    Background: The pathogenesis of Parkinson's disease (PD) is closely linked to ferroptosis, yet the mechanism by which ferroptosis‐related proteins modulate PD risk through genetic variations remains unclear. Methods: We performed two‐sample Mendelian randomization (MR) analyses using protein quantitative trait loci (pQTLs) from the UKB‐PPP and deCODE studies as instrumental variables, combined with PD genome‐wide association study (GWAS) data. The inverse variance weighting (IVW) method served as the primary analytical approach to identify PD‐associated proteins. To assess the role of ferroptosis‐related proteins in PD, a two‐step MR mediation analysis was conducted, followed by multiple sensitivity analyses. Transcriptomic datasets were analyzed to confirm the differential expression of genes encoding prioritized proteins. Publicly available single‐cell RNA sequencing data were utilized to investigate cell‐type‐specific expression patterns and functional pathways of key proteins. Results: A total of 210 proteins significantly associated with PD were identified ( p β = −0.503, p = 5.8 × 10 −4 ) through upregulating PARP16 expression ( β = 0.318, p = 2.36 × 10 −18 ), with CCNE1's differential expression further validated in transcriptomic datasets. Single‐cell analysis demonstrated that CCNE1 and PARP16 are specifically highly expressed in neurons ( p < 0.05), with neurons being significantly enriched in neural survival and synaptic plasticity pathways. The cell interaction network revealed that neurons specifically communicate with astrocytes via the NRG3‐ERBB4 pathway. Conclusion: This study provides the first molecular insight into how CCNE1 exerts neuroprotective effects through the regulation of the ferroptosis key protein PARP16, offering a novel perspective for PD mechanism research.


  • Open Access

    Exploring the mechanism of metabolic cell death-related genes AKR1C2 and MAP1LC3A as biomarkers in Parkinson’s disease

    by Jia Fu, Jing Zhao, Xue Zhao, Na Mi, Chao Zhang, Xueying Li, Lei Wu, Lige Han, Yali Zhang, Lifen Yao

    There is a strong relationship between metabolic cell death (MCD) and neurodegenerative diseases. However, the involvement of metabolic cell death (MCD)-related genes (MCDRGs) in Parkinson's disease (PD) pathogenesis remains poorly analyzed. Integrating PD-associated differentially expressed genes (DEGs) from GSE7621 with MCDRGs, we identified key biomarkers through protein-protein interaction networks and machine learning. Diagnostic performance was validated through nomogram analysis. Subsequent analyses included functional enrichment, immune profiling, drug prediction, and single-cell RNA sequencing. AKR1C2 and MAP1LC3A were identified as potential biomarkers. A nomogram with superior diagnostic performance was constructed. Gene set enrichment analysis indicated that both biomarkers were linked to the "Parkinson's disease". Further, immune infiltration revealed that AKR1C2 had the remarkably strongest positive correlation with M2 macrophages. Moreover, benzo[a]pyrene-1,6-dione, mestranol, and paraoxon-methyl might be potential therapeutic agents for PD. Single-cell RNA-seq analysis demonstrated endothelial-specific expression, with MAP1LC3A and AKR1C2 exhibiting distinct temporal regulation during differentiation. AKR1C2 and MAP1LC3A were identified as potential biomarkers associated with MCD in PD. These results offer fresh concepts for PD prevention and diagnosis.


  • Integrative multiomics elucidate crotonylation-associated GCDH in Parkinson’s disease pathogenesis via metabolome remodeling

    by Jia Fu, Jing Zhao, Na Mi, Chao Zhang, Yali Zhang, Lifen Yao

    The pathophysiological significance of crotonylation and its metabolomic regulatory circuitry in Parkinson’s disease (PD) remains elusive. We utilized Mendelian randomization (MR) frameworks combined with mediation analysis to establish causal links between crotonylation-associated genes and PD, while systematically delineating metabolite-mediated mechanisms. In this study, crotonylation-related genes were selected from the eQTLGen dataset, and their causal relationship with PD was assessed using two-sample MR analysis. Subsequently, we investigated metabolites associated with PD risk. Additionally, two-step MR and MR mediation analyses were applied to explore the mediating effects of crotonylation-related genes, metabolites, and PD. To further interpret cellular heterogeneity, publicly available GEO single-cell transcriptome data were integrated to analyze PD brain tissue dynamics and the regulatory mechanisms of key crotonylation-related genes. We identified 16 crotonylation-associated genes harboring cis-eQTLs, notably SIRT1, GCDH, and HDAC7, which demonstrated significant inverse associations with PD risk (p < 0.05). Through MR analysis, 74 PD-associated metabolites were identified. Mediation analysis further delineated GCDH-mediated PD risk reduction (βall = -0.054) through downregulation of X-21,471 and tetradecanedioate (C14-DC). Furthermore, single-cell transcriptomic analysis revealed that GCDH is predominantly and specifically highly expressed in astrocytes within PD brain tissues, and its dynamic regulatory pattern is closely linked to cell differentiation processes, suggesting a potential role in regulating PD pathogenesis via the NRG3-ERBB4 signaling axis. Our findings indicate that GCDH and its mediated metabolome critically contribute to PD pathogenesis, with astrocytes emerging as a central regulatory cell type. This study not only elucidates novel molecular landscapes underlying PD pathology but also highlights astrocytes as promising targets for therapeutic intervention.

  • Open Access

    Nomogram for predicting pregnancy-related relapse of myasthenia gravis

    by Manqiqige Su, Xiaoqing Liu, Zongtai Wu, Jie Song, Xiao Huan, Huahua Zhong, Rui Zhao, Chongbo Zhao, Yali Zhang, Sushan Luo

    Background: Myasthenia gravis (MG) is an autoimmune disease mediated by autoantibodies primarily affecting the neuromuscular junction. This study aims to identify risk factors for pregnancy-related MG relapse and develop a predictive model to improve clinical outcomes. Methods: We enrolled 113 MG female patients with a pregnancy history during follow-up at Huashan Hospital affiliated with Fudan University, between January 2015 and October 2021. The study analyzed relapse rates and risk factors during pregnancy and postpartum using multivariate logistic regression. A nomogram was constructed to predict relapse probability, with model performance evaluated by discrimination and calibration metrics. Results: Of the 113 patients, 52 (46.02%) experienced 115 relapses, including 52 (45.22%) occurring during the first trimester of pregnancy, 11 (9.56%) during the second trimester of pregnancy, and 52 relapses (45.22%) during the three months after delivery/abortion. Significant factors associated with pregnancy-relate relapse, included age at delivery/abortion (OR 0.21, 95% CI 0.06–0.65), MG stable duration (OR 0.24, 95% CI 0.09–0.63), thymic hyperplasia (OR 3.45, 95% CI 1.35–9.3), pre-pregnancy thymectomy (OR 0.08, 95% CI 0.01–0.36), and inadequate treatment during pregnancy (OR 4.44, 95% CI 1.35–17.76). The Nomogram model demonstrated robust predictive performance. Conclusion: The first trimester of pregnancy and three months following delivery or abortion are high-risk periods for MG relapse. Younger ages, shorter MG stable duration before pregnancy, thymic hyperplasia, and inadequate treatments during pregnancy increase relapse risk.


  • Open Access

    Metabolomic analysis of serum short-chain fatty acid concentrations in a mouse of MPTP-induced Parkinson’s disease after dietary supplementation with branched-chain amino acids

    by Na Mi, Lili Ma, Xueying Li, Jia Fu, Xinxin Bu, Fei Liu, Fan Yang, Yali Zhang, Lifen Yao

    The gut microbiota and microbial metabolites influence the enteric nervous system and the central nervous system via the microbial–gut–brain axis. Increasing body of evidence suggests that disturbances in the metabolism of peripheral branched-chain amino acids (BCAAs) can contribute to the development of neurodegenerative diseases through neuroinflammatory signaling. Preliminary research has shown that longitudinal changes in serum amino acid levels in mouse models of Parkinson’s disease (PD) are negatively correlated with disease progression. Therefore, the aim of the present study was to determine the changes in serum levels of short-chain fatty acids (SCFAs) in a mouse model of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD after dietary BCAA supplementation. In our research, gas chromatography–mass spectrometry was used to detect serum SCFA concentrations. The data were then analyzed with principal component analysis and orthogonal partial least squares discriminant analysis. Finally, the correlations of serum SCFA levels with gut and motor function in MPTP-induced PD mice were explored. Propionic acid, acetic acid, butyric acid, and isobutyric acid concentrations were elevated in MPTP + H-BCAA mice compared with MPTP mice. Propionic acid concentration was increased the most, while the isovaleric acid concentration was decreased. Propionic acid concentration was positively correlated with fecal weight and water content and negatively correlated with the pole-climbing duration. In conclusion, these results not only suggest that propionic acid may be a potential biomarker for PD, but also indicate the possibility that PD may be treated by altering circulating levels of SCFA.